Atopic dermatitis

Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress

Retrieved on: 
Saturday, October 2, 2021
AMGN, PHASE 2, EASI, Congress, Journal of the European Academy of Dermatology and Venereology, NASDAQ, Eczema Area and Severity Index, Atopic dermatitis, AMG, Safety, Venereology, Pharmaceutical industry, Copper

AMG 451/KHK4083 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic dermatitis.

Key Points: 
  • AMG 451/KHK4083 is a potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic dermatitis.
  • "I hope that future clinical development data will further elucidate the significance and potential of AMG 451/KHK4083 in the treatment of moderate-to-severe atopic dermatitis."
  • Dr. Emma Guttman-Yassky is the lead investigator of the study and a paid consultant for the AMG 451/KHK4083 development by Kyowa Kirin.
  • On June 1, 2021, Amgen and Kyowa Kirin entered into an agreement to jointly develop and commercialize AMG 451/KHK4083.

NEA's Eczema Awareness Month 2021 Explores The Heterogeneity Of This Life-altering Skin Disease That Burdens 1 In 10 Adults And Children In The USA

Retrieved on: 
Friday, October 1, 2021
People, JAMA Dermatology, Human, Mortality, AD, Pain, Systematic review, Health, Depression, Human voice, Multimedia, Association, Suicidal ideation, Disease, Suicide, Meta-analysis, Journal of the American Academy of Dermatology, Awareness, International Volcanic Ashfall Impacts Working Group, Global Burden of Disease Study, Patient, Anxiety, Sleep, Asthma, Prevalence, Veni, vidi, vici, Inflammation, E430, Equitable Access to Care and Health Act, Journal of the European Academy of Dermatology and Venereology, Caregiver, Access, Lived experience, Education, Individual, Social media, Burden, NEA, Singam, Atopic dermatitis, The Journal of Allergy and Clinical Immunology, Adult, View, Roger O. Egeberg, Research, Skin, Health insurance, Silk, Animal, Medicine, Pharmaceutical industry, Coffee

5, 6, 7, 8, 9

Key Points: 
  • 5, 6, 7, 8, 9
    Nearly 40% of patients with eczema reported that they turned down a job or an educational opportunity due to their disease.
  • NEA advances critical eczema research and partners with key stakeholders to ensure the patient voice is represented and valued in education, care and treatment decision-making.
  • Understanding the Lived Experience of Eczema: The "Voice of the Patient" Report on the Eczema Patient-Focused Drug Development Meeting.
  • Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis.

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

Retrieved on: 
Thursday, September 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, CEST, PASI, Week, Fibrosis, Congress, Journal of the European Academy of Dermatology and Venereology, JAK, CPU socket, Multimedia, Prior, TYK2, Apremilast, Â, Psoriasis Area and Severity Index, Dry, Itch, Psoriasis, Gaps, Immunology, Bristol Myers Squibb, Salford Royal NHS Foundation Trust, Pharmacology, Late, Disease, Comparative effectiveness research, Atopic dermatitis, Risk, Science, Research, Alopecia areata, PSSD, University, Jeff Flake, Neutrophil, BMY, NYSE, University of Manchester, Pharmaceutical industry, Deucravacitinib, the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies, Psoriasis, Bristol Myers Squibb, DEUCRAVACITINIB, THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 STUDIES, PSORIASIS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 October 2, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 October 2, 2021.
  • These data (Presentation #2857) are being presented today during the Late Breaking News Session from 3:45 4:45 p.m. CEST.
  • Bristol Myers Squibb-sponsored abstracts presented at EADVs 30th Anniversary Congress can be found below and accessed online here .
  • Visit this page on BMS.com for more information on Bristol Myers Squibbs scientific approach and resources on dermatologic immune-mediated diseases.

Dermavant Showcases New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof in Patients with Plaque Psoriasis at the 30th EADV Virtual Congress

Retrieved on: 
Thursday, September 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Linda, People, Food, Journal of the European Academy of Dermatology and Venereology, Week, Henry Ford, Efficiency, Dermatologic Clinics, Skin, Patient, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Plaque, Depression, FDA, QD, PGA, Henry Ford Health System, Adult, Hypertension, Vitiligo, Drug discovery, LinkedIn, Diabetes, Twitter, Remittance, Roivant Sciences, Psoriasis, Ageing, Acne, New Drug Application, Risk, Atopic dermatitis, Tachyphylaxis, Research, Maintenance, Obesity, Inflammatory bowel disease, Safety, Quality of life, Doctor of Philosophy, Global Assessment of Functioning, Yale School of Medicine, Pharmaceutical industry, Dermavant’s Phase 3 Program for Tapinarof in Psoriasis, Psoriasis, Dermavant, DERMAVANT’S PHASE 3 PROGRAM FOR TAPINAROF IN PSORIASIS, PSORIASIS, DERMAVANT

The data were presented during a Late-Breaking Session at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

Key Points: 
  • The data were presented during a Late-Breaking Session at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
  • Subjects who received tapinarof treatment during PSOARING 1 or 2 and completed PSOARING 3 received treatment for up to 52 weeks.
  • Greater than 90% of eligible patients who completed PSOARING 1 and PSOARING 2 enrolled in PSOARING 3.
  • The company has reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis, and has initiated a Phase 3 program in atopic dermatitis in patients aged 2 years and older.

RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

Retrieved on: 
Thursday, September 30, 2021
Inflammation, Therapy, Viga, Asthma, Pharmacokinetics, Research, Allergic rhinitis, Skin, Patient, Risk, Congress, Atopic dermatitis, European Academy of Allergy and Clinical Immunology, Cytokine, Security (finance), U.S. Securities and Exchange Commission, Cancer, BSA, Body surface area, Psoriasis Area and Severity Index, Biomarker, AD, Itch, CEO, FRCPC, RAPT, Hives, SAN, Disease, Journal of the European Academy of Dermatology and Venereology, Ligand, Kinetics, Numerical, Sinusitis, Tissue, Eczema Area and Severity Index, Safety, Forward-looking statement, CCR4, Quality of life, Eosinophilic esophagitis, NRS, Protein, GLOBE, Pharmaceutical industry, Vaccine

We look forward to initiating our Phase 2b clinical trial in atopic dermatitis and to expanding our exploration of RPT193 in a Phase 2a trial in asthma.

Key Points: 
  • We look forward to initiating our Phase 2b clinical trial in atopic dermatitis and to expanding our exploration of RPT193 in a Phase 2a trial in asthma.
  • The Phase 1b study reported today was part of RAPTs first-in-human Phase 1a/1b trial of RPT193.
  • The Phase 1b portion of the trial was a randomized, double-blind, placebo-controlled study examining RPT193 as monotherapy in patients with moderate-to-severe AD.
  • The Phase 1a portion of the Phase 1a/1b trial was a standard single and multiple dose-escalation study in healthy volunteers.

New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

Retrieved on: 
Thursday, September 30, 2021
Viga, Schleswig-Holstein, Week, Patient, Solution, European Academy of Allergy and Clinical Immunology, Congress, Psoriasis Area and Severity Index, Teaching hospital, Disease, Atopic dermatitis, HD, Incidence, Safety, Department, Vaccine, Medical device, Pharmaceutical industry

These early results are exciting, and we look forward to seeking confirmatory data in future amlitelimab clinical trials.

Key Points: 
  • These early results are exciting, and we look forward to seeking confirmatory data in future amlitelimab clinical trials.
  • Eligible patients included adults with moderate-to-severe atopic dermatitis whose disease is inadequately controlled with topical therapies such as corticosteroids, or where such therapies were not advisable.
  • "This Phase 2a trial is the foundation of our clinical trial program with amlitelimab in atopic dermatitis.
  • The forthcoming global Phase 2b trial will further evaluate the impact of amlitelimab when given subcutaneously in patients with moderate-to-severe atopic dermatitis.

Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Retrieved on: 
Thursday, September 30, 2021
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Janus, MHRA, Food, Clinical trial, Review, Vaccine, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, European Medicines Agency, JAK, Inflammation, News, U.S. Securities and Exchange Commission, Patient, Fortis Healthcare, LinkedIn, YouTube, Dermatitis, AD, Skin, JAK1, Twitter, Ageing, European Union, Erythema, TSLP, MHLW, Atopic dermatitis, Janus kinase 1, Science, COVID-19, Facebook, Union, Research, Health care, Safety, Inc., PFE, NYSE, Pharmaceutical industry, Medical device, CIBINQO® (abrocitinib), Atopic Dermatitis, Pfizer: Breakthroughs That Change Patients’ Lives, CIBINQO® (ABROCITINIB), ATOPIC DERMATITIS, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

Our priority will now be to ensure CIBINQO is routinely accessible to as many patients as possible.

Key Points: 
  • Our priority will now be to ensure CIBINQO is routinely accessible to as many patients as possible.
  • The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted Great Britain marketing authorization for CIBINQO earlier this month.
  • Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of atopic dermatitis, including interleukin IL-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).
  • 2015;66(suppl 1):8-16.
    v Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Prevalence of atopic dermatitis in Japanese adults.

LEO Pharma presents interim data from Phase 3 tralokinumab long-term extension trial in moderate-to-severe atopic dermatitis at EADV 30th Congress

Retrieved on: 
Thursday, September 30, 2021
Health, FDA, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Food, Journal of the European Academy of Dermatology and Venereology, Medication, Tralokinumab, Skin, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Atopic dermatitis, Congress, DDI, III, Dermatitis, Association, LEO, MD, Adult, Psoriasis Area and Severity Index, Development, United States National Library of Medicine, DKK, Royal commission, Itch, American Academy, National library, AAD, Disease, Drug, Science, Leo Pharma, TCS, MBA, Research, European Commission, Health care, NOS, Safety, Interim, NRS, Pharmaceutical industry, Vaccine, tralokinumab, the ECZTEND - Long-Term Extension (LTE), ECZTRA 1 and ECZTRA 2 Trials, atopic dermatitis, LEO Pharma, TRALOKINUMAB, THE ECZTEND - LONG-TERM EXTENSION (LTE), ECZTRA 1 AND ECZTRA 2 TRIALS, ATOPIC DERMATITIS, LEO PHARMA

The data being presented at EADV are very encouraging because they showed that patients treated with tralokinumab maintained improvements in signs and symptoms of atopic dermatitis over several years.

Key Points: 
  • The data being presented at EADV are very encouraging because they showed that patients treated with tralokinumab maintained improvements in signs and symptoms of atopic dermatitis over several years.
  • Two-year Maintenance of Response with Tralokinumab in Moderate-to-Severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.
  • Tralokinumab for moderatetosevere atopic dermatitis: results from two 52week, randomized, doubleblind, multicentre, placebocontrolled phase III trials (ECZTRA 1 and ECZTRA 2).
  • Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials ECZTEND.

LEO Pharma presents new Adtralza® (tralokinumab) data following long-term continuous treatment at EADV 30th Congress

Retrieved on: 
Thursday, September 30, 2021
Health, Science, Pharmaceutical, Research, Clinical Trials, Journal of the European Academy of Dermatology and Venereology, Medication, Skin, Patient, EASI, Atopic dermatitis, Congress, DDI, III, Dermatitis, LEO, MD, Development, Adult, Psoriasis Area and Severity Index, DKK, Royal commission, Itch, Disease, Drug, COVID-19, Leo Pharma, Science, TCS, Severe acute respiratory syndrome coronavirus 2, MBA, Research, European Commission, Health care, NOS, Safety, EudraCT, Conditional sentence, NRS, Pharmaceutical industry, Vaccine, Adtralza (tralokinumab), the ECZTEND - Long-Term Extension (LTE), ECZTRA 1 and ECZTRA 2 Trials, atopic dermatitis, LEO Pharma, ADTRALZA (TRALOKINUMAB), THE ECZTEND - LONG-TERM EXTENSION (LTE), ECZTRA 1 AND ECZTRA 2 TRIALS, ATOPIC DERMATITIS, LEO PHARMA

The sustained response over two years further adds to the long-term efficacy profile of Adtralza, said Jrg Mller, Executive Vice President, Global Research and Development, LEO Pharma.

Key Points: 
  • The sustained response over two years further adds to the long-term efficacy profile of Adtralza, said Jrg Mller, Executive Vice President, Global Research and Development, LEO Pharma.
  • A decline in the median EASI percent improvement was observed in the washout cohort within the period without treatment.
  • Following the washout of treatment (>15 weeks), median EASI percent improvement (vs. parent trial baseline) declined to 68.6%.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Amgen To Webcast Investor Call At EADV 2021

Retrieved on: 
Wednesday, September 29, 2021
AMGN, Biotechnology, Internet, Solution, Congress, European Academy of Management, Therapy, Inflammation, NASDAQ, Webcast, Patient, Development, Biology, Disease, Journal of the European Academy of Dermatology and Venereology, Atopic dermatitis, Genetics, AMG, Calendar, Pharmaceutical industry, Broadcasting

THOUSAND OAKS, Calif., Sept. 29, 2021 /PRNewswire/ --Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress.

Key Points: 
  • THOUSAND OAKS, Calif., Sept. 29, 2021 /PRNewswire/ --Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress.
  • The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com , under Investors.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
  • The webcast will be archived and available for replay for at least 90 days after the event.